Covid19
Conditions
Keywords
neutralizing antibodies, long-term persistence
Brief summary
Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known. The investigators will explore patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected. The investigators will determine whether this persistance varies according to * the severity of the Covid-19 * a treatment by steroids during the covid-19. This will help to anticipate whether a second wave of infection is possible in a non-naive population.
Detailed description
Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known. The investigators will explore adult patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected. The investigators will determine whether this persistance varies according to * the severity of the Covid-19 (3 groups: no oxyegn therapy; oxygen therapy of less than 3L/min; oxygen therapy of 3L/min or more) * a treatment by steroids during the covid-19. Immunocompromised patients will be excluded.
Interventions
blood sample of 10 ml twice (6 and 12 months after the Covid-19)
Sponsors
Study design
Intervention model description
sample of patients 6 and 12 months after the acute disease
Eligibility
Inclusion criteria
* positive SARS-CoV-2
Exclusion criteria
* age under 18 * immunocompromised at the onset of Covid-19
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| anti-SARS-CoV-2 neutralizing antibody titers | 1 day | Titer in plamsa of neutralizing anti-SARS-CoV-2 antibody |